Hjem
Kenneth Dicksteins bilde

Kenneth Dickstein

Professor
  • E-postKenneth.Dickstein@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) 2019. Sex-related procedural aspects and complications in CRT survey II: A multicenter European experience in 11,088 patients. JACC: Clinical Electrophysiology. 1048-1058.
  • Vis forfatter(e) 2019. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure. 1-11.
  • Vis forfatter(e) 2019. Proenkephalin, an opioid system surrogate, as a novel comprehensive renal marker in heart failure. Circulation: Heart Failure. 1-13.
  • Vis forfatter(e) 2019. Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. European Journal of Heart Failure. 1-11.
  • Vis forfatter(e) 2019. Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. European Heart Journal. 3616-3625.
  • Vis forfatter(e) 2019. Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. European journal of internal medicine. 8 sider.
  • Vis forfatter(e) 2019. Comparison of current German and European practice in cardiac resynchronization therapy: lessons from the ESC/EHRA/HFA CRT Survey II. Clinical Research in Cardiology. 1-13.
  • Vis forfatter(e) 2019. Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study. European Journal of Heart Failure. 81-89.
  • Vis forfatter(e) 2018. Waist-to-hip ratio and mortality in heart failure. European Journal of Heart Failure. 1269-1277.
  • Vis forfatter(e) 2018. Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure: Findings from the EPHESUS and OPTIMAAL trials. Journal of Hypertension. 1736-1742.
  • Vis forfatter(e) 2018. Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. Clinical Proteomics. 1-9.
  • Vis forfatter(e) 2018. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. European Journal of Heart Failure. 888-895.
  • Vis forfatter(e) 2018. Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. Journal of the American College of Cardiology. 727-735.
  • Vis forfatter(e) 2018. Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction. International Journal of Cardiology. 260-266.
  • Vis forfatter(e) 2018. Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction Database Initiative). American Journal of Cardiology. 1015-1020.
  • Vis forfatter(e) 2018. Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. European Journal of Heart Failure. 260-267.
  • Vis forfatter(e) 2018. Potassium and the use of renin?angiotensin?aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. European Journal of Heart Failure. 923-930.
  • Vis forfatter(e) 2018. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology.
  • Vis forfatter(e) 2018. Interaction of left ventricular size and sex on outcome of cardiac resynchronization therapy among patients with a narrow QRS duration in the EchoCRT trial. Journal of the American Heart Association (JAHA). 1-16.
  • Vis forfatter(e) 2018. Indications for cardiac resynchronization therapy: a comparison of the major international guidelines. JACC. Heart failure. 308-316.
  • Vis forfatter(e) 2018. Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction. Journal of the American College of Cardiology. 1081-1090.
  • Vis forfatter(e) 2018. Heart rate, pulse pressure and mortality in patients with myocardial infarction complicated by heart failure. International Journal of Cardiology. 181-185.
  • Vis forfatter(e) 2018. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. European Journal of Heart Failure. 1-11.
  • Vis forfatter(e) 2018. Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study. European Journal of Heart Failure. 1-9.
  • Vis forfatter(e) 2018. Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. International Journal of Cardiology. 84-90.
  • Vis forfatter(e) 2018. European crt survey II - bulgarian data. Comptes Rendus de l'Academie Bulgare des Sciences. 859-864.
  • Vis forfatter(e) 2018. Effectiveness of the European Society of Cardiology/Heart Failure Association website 'heartfailurematters.org' and an e-health adjusted care pathway in patients with stable heart failure: results of the 'e-Vita HF' randomized controlled trial. European Journal of Heart Failure. 1-9.
  • Vis forfatter(e) 2018. Croatian National Data and Comparison with European Practice: Data from the Cardiac Resynchronization Therapy Survey II Multicenter Registry. Cardiology Research and Practice. 8 sider.
  • Vis forfatter(e) 2018. Coronary angiography in worsening heart failure: Determinants, findings and prognostic implications. Heart. 606-613.
  • Vis forfatter(e) 2018. Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. European Heart Journal. 3867-3875.
  • Vis forfatter(e) 2018. Clinical practices and attitudes regarding the diagnosis and management of heart failure: findings from the CORE Needs Assessment Survey. ESC Heart Failure. 172-183.
  • Vis forfatter(e) 2018. Cardiac resynchronization therapy in patients with heart failure and narrow QRS complexes. Journal of the American College of Cardiology. 1325-1333.
  • Vis forfatter(e) 2018. Cardiac Resynchronisation Therapy (CRT) Survey II: CRT implantation in Europe and in Switzerland. Swiss Medical Weekly.
  • Vis forfatter(e) 2018. CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how? European Journal of Heart Failure. 1039-1051.
  • Vis forfatter(e) 2018. Biomarker-guided versus guideline-based treatment of patients with heart failure: Results from BIOSTAT-CHF. Journal of the American College of Cardiology. 386-398.
  • Vis forfatter(e) 2018. Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure (from BIOSTAT-CHF). European Journal of Heart Failure.
  • Vis forfatter(e) 2018. Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. European Journal of Heart Failure. 136-147.
  • Vis forfatter(e) 2017. The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis. Journal of the American College of Cardiology. 2128-2136.
  • Vis forfatter(e) 2017. Role of B-type natriuretic peptide and N-terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus. Journal of the American Heart Association (JAHA). 1-29.
  • Vis forfatter(e) 2017. Prognostic value of N-terminal pro-B-type natriuretic peptide levels in heart failure patients with and without atrial fibrillation. Circulation: Heart Failure. 1-10.
  • Vis forfatter(e) 2017. Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: A subanalysis of the randomized EchoCRT trial. European Heart Journal. 720-726.
  • Vis forfatter(e) 2017. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. European Journal of Heart Failure. 1284-1293.
  • Vis forfatter(e) 2017. Highly increased Troponin i levels following high-intensity endurance cycling may detect subclinical coronary artery disease in presumably healthy leisure sport cyclists: The North Sea Race Endurance Exercise Study (NEEDED) 2013. European Journal of Preventive Cardiology (EJPC). 885-894.
  • Vis forfatter(e) 2017. Effect of ularitide on cardiovascular mortality in acute heart failure. New England Journal of Medicine. 1956-1964.
  • Vis forfatter(e) 2017. Effect of cardiac resynchronization therapy in patients with diabetes randomized in EchoCRT. European Journal of Heart Failure. 80-87.
  • Vis forfatter(e) 2017. Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. European Journal of Heart Failure. 627-634.
  • Vis forfatter(e) 2017. Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative. Clinical Research in Cardiology. 722-733.
  • Vis forfatter(e) 2017. A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High-Risk MI Database. European Journal of Heart Failure. 635-642.
  • Vis forfatter(e) 2016. What does the lay public know about heart failure? Findings from the Heart Failure Awareness Day Initiative. European Journal of Heart Failure. 66-70.
  • Vis forfatter(e) 2016. What constitutes optimal neurohumoral antagonism in chronic heart failure? Heart. 1922-1932.
  • Vis forfatter(e) 2016. Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine.
  • Vis forfatter(e) 2016. Relation of longitudinal changes in quality of life assessments to changes in functional capacity in patients with heart failure with and without anemia. American Journal of Cardiology. 1482-1487.
  • Vis forfatter(e) 2016. Natriuretic peptide levels taken following unplanned admission to a cardiology department predict the duration of hospitalization. European Journal of Heart Failure. 1499-1505.
  • Vis forfatter(e) 2016. Geographic differences in patients in a global acute heart failure clinical trial (from the ASCEND-HF Trial). American Journal of Cardiology. 1771-1778.
  • Vis forfatter(e) 2016. Effect of gender on outcomes after cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Circulation: Arrhythmia and Electrophysiology.
  • Vis forfatter(e) 2016. Circulating galectin-3 levels are increased in patients with ischemic heart disease, but are not influenced by acute myocardial infarction. Cardiology. 398-405.
  • Vis forfatter(e) 2016. Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: A subgroup analysis of the EchoCRT trial. European Heart Journal. 49-59.
  • Vis forfatter(e) 2016. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine. 1521-1532.
  • Vis forfatter(e) 2016. Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. Journal of the American College of Cardiology. 1444-1455.
  • Vis forfatter(e) 2016. A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. European Journal of Heart Failure. 716-726.
  • Vis forfatter(e) 2012. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic HeartFailure 2012 of the European Society of Cardiology. Developed in collaborationwith the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure. 803-869.
  • Vis forfatter(e) 2012. ESC Guidelines for the management of acute myocardial infarction in patientspresenting with ST-segment elevation. European Heart Journal. 2569-2619.
  • Vis forfatter(e) 2012. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic HeartFailure 2012 of the European Society of Cardiology. Developed in collaborationwith the Heart Failure Association (HFA) of the ESC. European Heart Journal. 1787-1847.
  • Vis forfatter(e) 2012. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace. 1236-1286.
  • Vis forfatter(e) 2012. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm. 1524-1576.
  • Vis forfatter(e) 2010. Update of ESC guidelines regarding usage of devices in patients with heart failure-2010. Kardiologia polska. S475-S486.
  • Vis forfatter(e) 2008. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. The Lancet. 547-553.
  • Vis forfatter(e) 2006. Rapid implementation of therapeutic hypothermia in comatose out-of-hospital cardiac arrest survivors. Acta Anaesthesiologica Scandinavica. 1277-1283.
  • Vis forfatter(e) 2006. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. American Heart Journal. 927e1-927e6.
  • Vis forfatter(e) 2005. Soluble CD40 ligand in acute and chronic heart failure. European Heart Journal. 1101-1107.
  • Vis forfatter(e) 2005. Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. Journal of the American College of Cardiology. 2018-2021.
  • Vis forfatter(e) 2005. Is eplerenone a cost-effective therapy for heart failure patients after myocardial infarction? Nature Clinical Practice Cardiovascular Medicine. 440-441.
  • Vis forfatter(e) 2005. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. European Heart Journal. 650-61.
  • Vis forfatter(e) 2005. Exercise training in congestive heart failure. A review of the current status. Minerva Cardioangiologica : a Journal on Cardiovascular Pathophysiology, Clinical Medicine and Therapy. 275-286.
  • Vis forfatter(e) 2004. The data monitoring experience in the MOXCON trial. European Heart Journal. 174-178.
  • Vis forfatter(e) 2004. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. New England Journal of Medicine. 1285-1295.
  • Vis forfatter(e) 2004. Prognostic value of osteoprotegerin in heart failure following acute myocardial infarction. Journal of the American College of Cardiology. 1970-1976.
  • Vis forfatter(e) 2004. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. Journal of the American College of Cardiology. 1970-1976.
  • Vis forfatter(e) 2004. Effects of losartan and captopril on morbidity and mortality after acute MI. Cardiology Review. 23-29.
  • Vis forfatter(e) 2004. Effect of single doses of SLV306, an inhibitor of both neutral enclopepticlase and enclothelin-converting enzyme, on pulmonary pressures in congestive heart failure. American Journal of Cardiology. 237-240.
  • Vis forfatter(e) 2004. Effect of exercise training in patients with heart failure: a pilot study on autonomous balance assessed by heart rate variability. Journal of Cardiovascular Risk. 162-167.
  • Vis forfatter(e) 2004. Effect of exercise training in patients with heart failure: a pilot study on autonomic balance assessed by heart rate variability. Journal of Cardiovascular Risk. 162-167.
  • Vis forfatter(e) 2004. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. American Journal of Cardiology. 603-606.
  • Vis forfatter(e) 2004. Comparison of mortality rates after acute myocardial infarction in smokers versus nonsmokers. American Journal of Cardiology. 632-636.
  • Vis forfatter(e) 2003. Prognostic usefulness of an increase of N-terminal proatrial natriuretic peptide during exercise in patients with chronic heart failure. American Journal of Cardiology. 91-94.
  • Vis forfatter(e) 2003. Prognostic usefulness of an increase in N-terminal proatrial natriuretic peptide during exercise in patients with chronic heart failure. American Journal of Cardiology. 91-94.
  • Vis forfatter(e) 2003. Plasma chromogranin A concentration as an indicator of long-term mortality after acute myocardial infarction. American Journal of Medicine. 25-30.
  • Vis forfatter(e) 2003. Neurohumoral inhibition in heart failure; is there no limit? European Heart Journal. 1705-1706.
  • Vis forfatter(e) 2003. N-terminal proatrial natriuretic peptide in primary care: relation to echocardiographic indices of cardiac function in mild to moderate cardiac disease. International Journal of Cardiology. 197-205.
  • Vis forfatter(e) 2003. N-terminal proatrial natriuretic peptide in primary care: relation to echocardiographic indices of cardiac function in mild to moderate cardiac disease. International Journal of Cardiology. 197-205.
  • Vis forfatter(e) 2003. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. American Journal of Medicine. 25-30.
  • Vis forfatter(e) 2003. Association between plasma chromogranin A and long-term mortality after myocardial infarction. American Journal of Medicine. 25-30.
  • Vis forfatter(e) 2002. Prioritering av sykehusobduksjon. Tidsskrift for Den norske legeforening. 2787-2790.
  • Vis forfatter(e) 2002. How do heart failure patients die? European Heart Journal. D59-D65.
  • Vis forfatter(e) 2002. For the OPTIMAAL trial: losartan or captopril after acute myocardial infarction. The Lancet. 1885.
  • Vis forfatter(e) 2002. Effects of losatan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. The Lancet. 752-760.
  • Vis forfatter(e) 2002. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. The Lancet. 752-760.
  • Vis forfatter(e) 2002. Effect of exercise training on skeletal muscle fibre characteristics in men with chronic heart failure. Correlation between skeletal muscle alterations, cytokines and exercise capacity. International Journal of Cardiology. 25-32.
  • Vis forfatter(e) 2002. Characteristics and prognostic impact of plasma fibrin monomer (soluble fibrin) in patients with coronary artery disease. Blood Coagulation and Fibrinolysis. 301-308.
  • Vis forfatter(e) 2001. The role of losartan in the management of patients with heart failure. Clinical Therapeutics. 1456-1477.
  • Vis forfatter(e) 2001. How long should ACE inhibitors be given to patients following myocardial infarction: Implications of HOPE. Controlled Clinical Trials. 151-154.
  • Vis forfatter(e) 2001. Fibrin monomer (soluble fibrin) as a marker of coagulation activation in patients with acute chest pain syndromes. Clinical Chemistry.
  • Vis forfatter(e) 2001. Effect of simvastatin in preventing progression of carotid artery stenosis. American Journal of Cardiology. 643-646.
  • Vis forfatter(e) 2001. Effect of aerobic exercise training on plasma levels of tumor necosis factor alpha in patients with heart failure. American Journal of Cardiology. 805-808.
  • Vis forfatter(e) 2001. ELITE II and ValHeft; Together what do they tell us? Controlled Clinical Trials. 240-243.
  • Vis forfatter(e) 2001. Digitalis ved hjertesvikt - fortsatt et aktuelt behandlingsprinsipp? Tidsskrift for Den norske legeforening. 212-214.
  • Vis forfatter(e) 2001. Comparison of baseline data, initial course, and management: Losartan vs. Captopril following acute myocardial infarction (The OPTIMAAL Trial). American Journal of Cardiology. 766-771.
  • Vis forfatter(e) 2001. Comparison of baseline data, Initial course, and mannagment: Losartan Versus captopril following acute myocardial infarction (The OPTIMAAL Trial). American Journal of Cardiology. 766-771.
  • Vis forfatter(e) 2001. Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma. American Journal of Ophthalmology. 626-632.
  • Vis forfatter(e) 2001. Assessing the effect of exercise training in men with heart failure. Comparison of maximal, submaximal and endurance protocols. European Heart Journal. 684-692.
  • Vis forfatter(e) 2001. AllAs in congestive heart failure: Insights from ELITE II and ValHeft. Receptors in Cardiovascular Disease. 7.
  • Vis forfatter(e) 2000. The use of angiotensin II receptor antagonists in heart failure. Tidsskrift for Den norske legeforening. 817-821.
  • Vis forfatter(e) 2000. The Effects of Chronic, Sustained-release Moxonidine Therapy on Clinical and Neurohumoral Status in Patients with Heart Failure. International Journal of Cardiology. 167-176.
  • Vis forfatter(e) 2000. The Effects of Chronic, Sustained-release Moxonidine Therapy on Clinical and Neurohumoral Status in Patients with Heart Failure. International Journal of Cardiology. 167-176.
  • Vis forfatter(e) 2000. Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Survival Study - ELITE II. The Lancet. 1582-1587.
  • Vis forfatter(e) 2000. Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Survival Study - ELITE II. The Lancet. 1582-1587.
  • Vis forfatter(e) 2000. Plasma chromogranin A is an independent predictor of survival after acute myocardial infarction. European Heart Journal. 584.
  • Vis forfatter(e) 2000. Plasma brain natriuretic peptide as a prognostic indicator in patients with preserved left ventricular systolic function after acute myocardial infarction. Circulation. 609.
  • Vis forfatter(e) 2000. Pharmacotherapy following myocardial infarction - a review of current treatment practices. Expert Opinion on Pharmacotherapy. 1105-1116.
  • Vis forfatter(e) 2000. Pharmacotherapy following myocardial infarction - a review of current treatment practices. Exp Opin Pharmacother. 1105-1116.
  • Vis forfatter(e) 2000. Losartan vs. Captopril in patients following Acute Myocardial Infarction: The OPTIMAL Trial Design. Receptors in Cardiovascular Disease. 4-9.
  • Vis forfatter(e) 2000. Losartan vs. Captopril in patients following Acute Myocardial Infarction: The OPTIMAL Trial Design. Receptors in Cardiovascular Disease. 4-9.
  • Vis forfatter(e) 2000. Improvements in quality of life of symptomatic heart failure patients treated long-term with losartan and captopril: the ELITE II quality of life substudy. European Heart Journal. 464.
  • Vis forfatter(e) 2000. Exercise training in heart failure. Time to go beyond surrogate endpoints. European Journal of Heart Failure. 5-6.
  • Vis forfatter(e) 2000. Exercise training in heart failure. Time to go beyond surrogate endpoints. European Journal of Heart Failure. 5-6.
  • Vis forfatter(e) 2000. Er øyeblikkelig hjelp-innleggelser i medisinks avdeling avhengig av været? Tidsskrift for Den norske legeforening. 3678-3679.
  • Vis forfatter(e) 2000. Effects of moxonidine, a novel imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure. Journal of the American College of Cardiology. 398-404.
  • Vis forfatter(e) 2000. Effects of moxonidine, a novel imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure. Journal of the American College of Cardiology. 398-404.
  • Vis forfatter(e) 2000. Effects of exercise training on maximal and submaximal endurance capacity in men with congestive heart failure. European Journal of Heart Failure. In press.
  • Vis forfatter(e) 2000. Effect of simvastatin in preventing progression of carotid artery stenosis. American Journal of Cardiology. 17-20.
  • Vis forfatter(e) 2000. Effect of aerobic exercise training on cytokine levels in patients with congestive heart failure. European Heart Journal. 234.
  • Vis forfatter(e) 2000. Bruk av angiotensin II - reseptorblokkere ved hjertesvikt. Tidsskrift for Den norske legeforening. 817-821.
  • Vis forfatter(e) 2000. Are emergency medical admissions dependent on the weather? Tidsskrift for Den norske legeforening. 355-357.
  • Vis forfatter(e) 2000. Angiotensin II antagonists are superior to ACE inhibitors. David versus Golitah. European Journal of Heart Failure. 235-236.
  • Vis forfatter(e) 2000. Angiotensin II antagonists are superior to ACE inhibitors. David versus Golitah. European Journal of Heart Failure. 235-236.
  • Vis forfatter(e) 1999. Kronisk hjertesvikt - forslag til handlingsprogram. Tidsskrift for Den norske legeforening. 3427-3431.
  • Vis forfatter(e) 1999. Comparison of the effects of Losartan and Captopril on mortality in patients after acute myocardial infarction: The OPTIMAAL Trial Design. American Journal of Cardiology. 1-5.
  • Vis forfatter(e) 1997. Treatment of heart failure with beta-adrenergic blocking drugs. Tidsskrift for Den norske legeforening. 526-528.
  • Vis forfatter(e) 1997. Plasma N-terminal atrial natriuretic factor: a predictor of survival in patients with congestive heart failure. Journal of Cardiac Failure. 83-89.
  • Vis forfatter(e) 1997. Effects of angiotensin II receptor blockage on N- terminal proatrial natriuretic factor plasma levels in chronic heart failure. Journal of Cardiac Failure. 75-81.
  • Vis forfatter(e) 1997. Digitalis - et gammelt, men stadig aktuelt medikament. Therapia medica. 16-18.
  • Vis forfatter(e) 1997. Calcium channel blockers in heart failure. Tidsskrift for Den norske legeforening. 2329-2332.
  • Vis forfatter(e) 1997. Betablokkerbehandling av hjertesviktpasienter. Tidsskrift for Den norske legeforening. 526-528.
  • Vis forfatter(e) 1996. Pro-atrial natriuretisk faktor i plasma er prediktiv for klinisk status hos hjertesviktpasienter. Tidsskrift for Den norske legeforening. 1562-1566.
  • Vis forfatter(e) 1993. The effect of early converting enzyme inhibition on neurohumoral activycation in acute myocardial infarction. International Journal of Cardiology. 37-45.
Vitenskapelig foredrag
  • Vis forfatter(e) 2008. C-reactive protein, infarct size, microvascular obstruction and left ventricular remodeling following acute myocardial infarction.
  • Vis forfatter(e) 2005. Living with an implantable cardioverter defibrillator: A qualitative study from one Norwegian centre.
  • Vis forfatter(e) 2002. The role of angiotensin II antagonists in heart failure and following myocardial infarction.
  • Vis forfatter(e) 2002. State of the art management of myocardial infarction.
  • Vis forfatter(e) 2002. Results of recent trials in patients with heart failure following myocardial infarction.
  • Vis forfatter(e) 2002. Outpatient heart failure management programs – 4 models New markers of heart failure Determinants of long-term prognosis in heart failure Emerging therapies for heart failure.
  • Vis forfatter(e) 2002. Modern Aspects of Heart Failure Management. Recent Acheivements and Future Directions.
  • Vis forfatter(e) 2002. Controlling the course of disease in the post-myocardial infarction patient: the OPTIMAAL trial.
  • Vis forfatter(e) 2002. Comparison of the Effects of Losartan and Captopril on Mortality and Morbidity in patients following Acute Myocardial Infarction: The OPTIMAAL Trial.
  • Vis forfatter(e) 2002. Clinical implications of losartan in the OPTIMAAL study.
  • Vis forfatter(e) 2002. Beta-blockers should be withdrawn in decompensated heart failure patients.
  • Vis forfatter(e) 2002. Angiotensin II antagonists; are they established therapy in heart failure?
  • Vis forfatter(e) 2002. ARBs are as good as ACE inhibitors.
  • Vis forfatter(e) 2001. Effect of exercise training on muscle fibre characteristics in patients with heart failure.
  • Vis forfatter(e) 1996. N-terminal probrain natriuretic peptide - a new marker of cardiac function and prognosis.
Sammendrag/abstract
  • Vis forfatter(e) 2013. The association between heart rate, pulse pressure and clinical outcomes in 16503 patients with myocardial infarction complicated by signs of heart failure or left ventricular dysfunction. European Heart Journal. 349-349.
  • Vis forfatter(e) 2013. Early discharge (< 3 days) following primary PCI is safe in low risk patients. European Heart Journal. 246-246.
  • Vis forfatter(e) 2013. ESC Heart Failure Guidelines 2012-a review. Journal of Cardiac Failure. S106-S107.
  • Vis forfatter(e) 2010. Smokers spend shorter time in hospital than non-smokers following complicated AMI. European Heart Journal. 683-683.
  • Vis forfatter(e) 2010. Predicting Adverse Effects during Angiotensin Receptor Blocker Treatment in Heart Failure: Results from the HEAAL Trial. Journal of Cardiac Failure. S73-S74.
  • Vis forfatter(e) 2010. Peripheral artery disease as a predictor of outcome in high-risk MI patients: pooled analysis from the high risk MI database initiative (pooled data from CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT). European Heart Journal. 604-604.
  • Vis forfatter(e) 2010. NT-proBNP is a potent prognostic marker in patients with type 2 diabetes hospitalized for acute coronary syndrome - a DIGAMI 2 sub study. European Heart Journal. 514-515.
  • Vis forfatter(e) 2010. Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction and prevents ischemic heart failure. European Heart Journal. 314-314.
  • Vis forfatter(e) 2010. Intravenous ferric carboxymaltose improves quality of life in patients with chronic heart failure and iron deficiency regardless the presence of anaemia: an analysis from the FAIR-HF study. European Heart Journal. 233-233.
  • Vis forfatter(e) 2010. Early increase in Stromelysin-1 levels is related to infarct size and predicts long-term LV remodelling following STEMI. European Heart Journal. 192-193.
  • Vis forfatter(e) 2010. Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Circulation. 2217-2217.
  • Vis forfatter(e) 2009. Circulating Markers of Collagen Turnover Following ST-Segment Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention Predict Infarct Size and Left Ventricular Volumes, Estimated by Serial Cardiac Magnetic Resonance Imaging for up to 1 Year. Circulation. S818-S818.
  • Vis forfatter(e) 2007. The relationship between N-terminal B-type natriuretic peptide and circulating markers of extracellular cardiac remodelling in patients following complicated myocardial infarction. European Journal of Heart Failure. 10-11.
  • Vis forfatter(e) 2004. What's new in the management of heart failure? Atherosclerosis Supplements.
  • Vis forfatter(e) 2004. Total mortality and sudden cardiac death are predicted by both left and right bundle branch block at baseline and during follow-up after complicated myocardial infarction. Circulation. A1032-A1032.
  • Vis forfatter(e) 2004. The relationship between the extent of myocardial scarring and left ventricular ejection fraction assessed by cardiac magnetic resonance in 57 patients with previous myocardial infarction. European Heart Journal. 599-599.
  • Vis forfatter(e) 2004. The longitudinal profile of markers of cardiac extracellular matrix turnover in patients following acute myocardial infarction. European Heart Journal.
  • Vis forfatter(e) 2004. Relative impact of renal function on circulating levels of brain-type natriuretic peptide an N-terminal-pro-brain-type natriuretic peptide in patients with postinfarction heart failure. European Heart Journal. 292-292.
  • Vis forfatter(e) 2004. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction. The OPTIMAL experience. European Heart Journal. 299-299.
  • Vis forfatter(e) 2004. Moderate alcohol use is associated with reduced cardiovascular risk in patients following complicated acute myocardial infarction. JACC. 1153-1173.
  • Vis forfatter(e) 2004. Hemoglobin levels predict survival and hospitalization after a complicated acute myocardial infarction: Results from the OPTIMAAL study. Circulation. 574-575.
  • Vis forfatter(e) 2004. Haemoglobin levels predict survival and hospitalisation after a complicated acute myocardial infarction: results from the OPTIMAAL study. European Heart Journal. 305-305.
  • Vis forfatter(e) 2004. Effect of hypo- and hyperkalemia on mode of death in patients with heart failure following myocardial infarction. European Heart Journal.
  • Vis forfatter(e) 2003. Serial high-sensitivity CRP measurements and long-term prognosis in postinfarction heart failure. The OPTIMAAL neurohormonal substudy. Circulation.
  • Vis forfatter(e) 2003. Serial high-sensitivity CRP measurements and long-term prognosis in post-infarction heart failure. The OPTIMAAL neurohormonal study. Circulation. 692-692.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) 2020. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 407-477.
  • Vis forfatter(e) 2019. Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. The Lancet. 1045-1055.
  • Vis forfatter(e) 2016. Telerehabilitation in heart failure patients: The evidence and the pitfalls. International Journal of Cardiology. 408-413.
  • Vis forfatter(e) 2015. The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. International Journal of Cardiology. 256-264.
  • Vis forfatter(e) 2013. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. European Journal of Heart Failure. 1082-1094.
  • Vis forfatter(e) 2012. The High-Risk Myocardial Infarction Database Initiative. Progress in cardiovascular diseases. 362-366.
  • Vis forfatter(e) 2010. Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure. 423-433.
  • Vis forfatter(e) 2008. Successful treatment of heart failure with devices requires collaboration. European Journal of Heart Failure. 1229-1235.
  • Vis forfatter(e) 2008. Overview of emerging pharmacologic agents for acute heart failure syndromes. European Journal of Heart Failure. 201-213.
  • Vis forfatter(e) 2008. Guidelines 2008 European Society of Cardiology on the diagnosis and treatment of acute and chronic heart failure. Kardiologia polska. S389-S454.
  • Vis forfatter(e) 2008. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal. 2388-442.
  • Vis forfatter(e) 2008. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Journal of Heart Failure. 933-989.
  • Vis forfatter(e) 2008. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Heart Journal. 2388-2442.
  • Vis forfatter(e) 2007. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 684-694.
  • Vis forfatter(e) 2005. Diagnosis and assessment of the heart failure patient: the cornerstone of effective management. European Journal of Heart Failure. 303-308.

Se fullstendig oversikt over publikasjoner i CRIStin.